Results 61 to 70 of about 7,490 (132)

Mycoplasmas and cancer [PDF]

open access: yes, 2014
The standard of care for patients suffering cancer often includes treatment with nucleoside analogues (NAs). NAs are internalized by cell-specific nucleobase/nucleoside transporters and, after enzymatic activation (often one or more phosphorylation steps)
Balzarini, Jan   +2 more
core  

Perspectives and Prospects in the Chemotherapy of Gastrointestinal Cancer [PDF]

open access: yes, 1967
5-Flourouracil (5-FU) is the best agent for the treatment of all gastrointestinal cancers but should be used with restraint, since severe toxicity does not guarantee increased response or survival time.
Regelson, William
core   +1 more source

Incidence of drug-induced liver injury in medical inpatients [PDF]

open access: yes, 2018
Objectives: Drug-induced liver injury (DILI) is a common concern. However, data on DILI epidemiology in inpatients are sparse. Methods: To investigate the incidence of DILI, we screened all patients in the pharmacoepidemiological inpatient database ...
Cavallaro, Marzia   +6 more
core  

Cytotoxic Properties of Anthraquinones (Nordamnacanthal and Damnacanthal) from Roots of Morinda Elliptica [PDF]

open access: yes, 2003
The study on the cytotoxic properties of nordamnacanthal and damnacanthal, the anthraquinones isolated from the roots of Morinda elliptica (family Rubiaceae) were carried out on several cancerous cell lines including CEM-SS (T-lymphoblastic leukaemia),
Saiful Yazan, Latifah
core  

Abstracts

open access: yes
Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +1 more source

Effects of daunorubicin, mitomycinC, azathioprine and cyclosporinA on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines [PDF]

open access: yes, 2018
Background: We wished to investigate the toxicity of four immunosuppressant and antimetabolic drugs, which are known to influence postoperative wound healing, on three different human ocular cell lines.
Garweg, Justus   +2 more
core  

Home - About - Disclaimer - Privacy